Harbour BioMed Adds Immuno-Oncology Veteran to Scientific Advisory Board
Event summary
- Harbour BioMed appointed Dr. Luisa Salter-Cid as Scientific Advisor on June 10, 2026.
- Dr. Salter-Cid brings 20+ years of experience in immunology and immuno-oncology from roles at Flagship Pioneering, Bristol Myers Squibb, and Gossamer Bio.
- She has led teams advancing over 20 compounds into clinical development and authored 90+ publications and patents.
- Currently a Venture Partner at Osage University Partners, she will advise on Harbour BioMed's antibody therapeutics pipeline.
The big picture
Harbour BioMed's appointment of Dr. Salter-Cid underscores its focus on strengthening its scientific advisory capabilities in immunology and immuno-oncology. Her extensive experience in advancing novel therapies aligns with Harbour BioMed's goal of expanding its pipeline of antibody therapeutics. This move comes as the biopharmaceutical industry increasingly relies on specialized advisory boards to navigate complex drug development landscapes and address unmet medical needs globally.
What we're watching
- Pipeline Acceleration
- How Dr. Salter-Cid's expertise will impact Harbour BioMed's ability to advance its differentiated antibody therapeutics.
- Strategic Insights
- Whether her experience in translating scientific insights into clinical-stage assets will bolster Harbour BioMed's next-generation drug development.
- Industry Positioning
- The pace at which Harbour BioMed can leverage her network to strengthen its global collaborations and co-development efforts.
Related topics